全文获取类型
收费全文 | 5429篇 |
免费 | 350篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 170篇 |
妇产科学 | 153篇 |
基础医学 | 611篇 |
口腔科学 | 129篇 |
临床医学 | 663篇 |
内科学 | 954篇 |
皮肤病学 | 65篇 |
神经病学 | 411篇 |
特种医学 | 151篇 |
外科学 | 680篇 |
综合类 | 42篇 |
一般理论 | 5篇 |
预防医学 | 615篇 |
眼科学 | 78篇 |
药学 | 355篇 |
中国医学 | 7篇 |
肿瘤学 | 658篇 |
出版年
2023年 | 29篇 |
2022年 | 47篇 |
2021年 | 110篇 |
2020年 | 93篇 |
2019年 | 112篇 |
2018年 | 138篇 |
2017年 | 115篇 |
2016年 | 110篇 |
2015年 | 140篇 |
2014年 | 194篇 |
2013年 | 290篇 |
2012年 | 344篇 |
2011年 | 382篇 |
2010年 | 242篇 |
2009年 | 192篇 |
2008年 | 360篇 |
2007年 | 351篇 |
2006年 | 351篇 |
2005年 | 311篇 |
2004年 | 304篇 |
2003年 | 280篇 |
2002年 | 254篇 |
2001年 | 90篇 |
2000年 | 60篇 |
1999年 | 77篇 |
1998年 | 68篇 |
1997年 | 64篇 |
1996年 | 50篇 |
1995年 | 51篇 |
1994年 | 45篇 |
1993年 | 43篇 |
1992年 | 48篇 |
1991年 | 60篇 |
1990年 | 48篇 |
1989年 | 24篇 |
1988年 | 28篇 |
1987年 | 37篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 30篇 |
1983年 | 19篇 |
1982年 | 24篇 |
1981年 | 16篇 |
1980年 | 22篇 |
1979年 | 9篇 |
1978年 | 12篇 |
1977年 | 9篇 |
1975年 | 8篇 |
1974年 | 8篇 |
1967年 | 8篇 |
排序方式: 共有5795条查询结果,搜索用时 15 毫秒
121.
Hilde M. Norum Annika E. Michelsen Tove Lekva Satish Arora Kari Otterdal Maria Belland Olsen Xiang Yi Kong Einar Gude Arne K. Andreassen Dag Solbu Kristjan Karason Gran Dellgren Lars Gullestad Pl Aukrust Thor Ueland 《American journal of transplantation》2019,19(4):1050-1060
Cardiac allograft vasculopathy (CAV) causes heart failure after heart transplantation (HTx), but its pathogenesis is incompletely understood. Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV. We hypothesized that circulating Notch ligands would be dysregulated after HTx. We studied circulating delta‐like Notch ligand 1 (DLL1) and periostin (POSTN) and CAV in de novo HTx recipients (n = 70) randomized to standard or EVR‐based, calcineurin inhibitor‐free immunosuppression and in maintenance HTx recipients (n = 41). Compared to healthy controls, plasma DLL1 and POSTN were elevated in de novo (P < .01; P < .001) and maintenance HTx recipients (P < .001; P < .01). Use of EVR was associated with a treatment effect for DLL1. For de novo HTx recipients, a change in DLL1 correlated with a change in CAV at 1 (P = .021) and 3 years (P = .005). In vitro, activation of T cells increased DLL1 secretion, attenuated by EVR. In vitro data suggest that also endothelial cells and vascular smooth muscle cells (VSMCs) could contribute to circulating DLL1. Immunostaining of myocardial specimens showed colocalization of DLL1 with T cells, endothelial cells, and VSMCs. Our findings suggest a role of DLL1 in CAV progression, and that the beneficial effect of EVR on CAV could reflect a suppressive effect on DLL1. Trial registration numbers— SCHEDULE trial: ClinicalTrials.gov NCT01266148; NOCTET trial: ClinicalTrials.gov NCT00377962. 相似文献
122.
Janne M. Rapola Timo J. Pellinen Pekka Koskinen Lauri Toivonen Markku S. Nieminen MD 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》1990,4(3):737-743
Summary Hemodynamic effects of intravenous and oral pindolol and atenolol were assessed in ten healthy volunteers by left ventricular echocardiography and systolic time intervals. Measurements were made at rest and during hand-grip-induced isometric exercise. Drug doses were pindolol 0.015 mg/kg intravenously and 10 mg/day orally, atenolol 0.1 mg/kg intravenously, and 50 mg/day orally.Heart rate at rest was reduced by both drugs. The reduction caused by atenolol during oral treatment was significantly greater (p<0.01). Intravenously only pindolol reduced mean arterial pressure. During oral treatment atenolol reduced the mean arterial pressure nonsignificantly. Both drugs lowered heart rate during isometric exercise, atenolol being significantly more effective. During oral treatment atenolol blunted the heart-rate reaction to exercise. Mean arterial pressure during isometric exercise rose slightly with both drugs after intravenous administration. During oral treatment only atenolol reduced the mean arterial pressure significantly. Intravenous atenolol reduced cardiac contractility at rest, indicated by significant decreases in fractional shortening, ejection fraction, and the mean velocity of circumferential fiber shortening. In contrast, intravenous pindolol and oral therapy with either drug did not change contractility. Intravenous atenolol raised total peripheral resistance. The preejection period/left ventricular ejection time ratio decreased with intravenous pindolol, while atenolol increased it.In conclusion, atenolol had more negative inotropic and chronotropic effects, especially after acute intravenous administration. Only atenolol reduced cardiac output and increased peripheral resistance. After repeated oral administration, these effects were less apparent. 相似文献
123.
Metsärinne KP Vehmaan-Kreula P Kovanen PT Saijonmaa O Baumann M Wang Y Nyman T Fyhrquist FY Eklund KK 《Arteriosclerosis, thrombosis, and vascular biology》2002,22(2):268-273
Subendothelial mast cells have been implicated in the pathogenesis of allergic inflammation, in atherosclerosis, and in the regulation of vascular tone. Because endothelin-1 (ET-1) is an important regulator of vascular tone and has also been implicated in the pathogenesis of atherosclerosis, we studied the role of mast cells in the metabolism of endothelial cell-derived ET-1. In mast cell-endothelial cell cocultures, activation of the mast cells with ensuing degranulation was accompanied by the increased expression of ET-1 mRNA in the endothelial cells, yet the immunoreactive ET-1 protein in the coculture medium disappeared almost completely during the 24-hour coculture. Activation of the mast cells with the ensuing degranulation resulted in proteolytic degradation of ET-1 by the 2 neutral proteases, chymase and carboxypeptidase A, of the exocytosed mast cell granules. With synthetic ET-1 and purified mast cell granule enzymes, efficient degradation of ET-1 by chymase and carboxypeptidase A was verified. These in vitro results imply a novel role for mast cell-derived neutral proteases in ET-1 metabolism and suggest that activated subendothelial mast cells are important local regulators of ET-1 metabolism. 相似文献
124.
125.
126.
127.
Kannisto S Laatikainen A Taivainen A Savolainen K Tukiainen H Voutilainen R 《European journal of endocrinology / European Federation of Endocrine Societies》2004,150(5):687-690
OBJECTIVE: Supraphysiological doses of exogenous glucocorticosteroids cause adrenocortical suppression. Dehydroepiandrosterone sulfate (DHEA-S) is the most abundant adrenal androgen and estrogen precursor. We studied to what extent inhaled glucocorticosteroid therapy for asthma decreases serum DHEA-S concentrations. DESIGN AND METHODS: We measured serum DHEA-S and cortisol concentrations in 101 adult patients with newly detected mild asthma before and after 2 and 12 weeks of treatment with inhaled glucocorticosteroids. The patients were randomized to receive budesonide 200 microg/day (low dose group, n=50) or 800 microg/day (high dose group, n=51) in two parallel groups double-blindly. RESULTS: In the low dose group, serum DHEA-S concentrations decreased from the baseline by a mean of 8 % (95 % confidence interval (CI), 3-13 %, P<0.01) after 2 weeks of therapy, and by 2 % (95 % CI, 9 % decrease to 5 % increase, NS) after 12 weeks. In the high dose group, the respective decreases were 16 % (95 % CI, 10-21 %, P<0.001) and 18 % (95 % CI, 12-24 %, P<0.001). The difference between the treatment groups was significant at both 2 and 12 weeks. During the 12 week treatment period the baseline concentrations of serum cortisol did not decrease in the low dose group, while in the high dose group the decrease was significant at 12 weeks (P<0.01), but not at 2 weeks. The forced expiratory volume in 1 s improved equally well in both groups. CONCLUSIONS: Inhaled budesonide decreased serum DHEA-S concentrations, which may indicate adrenocortical suppression. Reduced adrenal production of androgen and estrogen precursors may increase the risk of osteoporosis especially in postmenopausal women. 相似文献
128.
129.
130.
Fehr C Shirley RL Crabbe JC Belknap JK Buck KJ Phillips TJ 《Alcoholism, clinical and experimental research》2005,29(5):708-720
BACKGROUND: We previously mapped a quantitative trait locus (QTL) for ethanol preference drinking to mouse chromosome 2 (mapped with high confidence, LOD = 15.5, p = 3 x 10(-16)). The specific gene(s) in the QTL interval responsible for phenotypic variation in ethanol preference drinking has not been identified. METHODS: In the current study, we investigated the association of the syntaxin binding protein 1 gene (Stxbp1) with ethanol preference drinking and other ethanol traits using a panel of B6 x D2 (BXD) recombinant inbred (RI) strains derived from the C57BL/6J (B6) and DBA/2J (D2) inbred mouse strains. Confirmation analyses for ethanol consumption and withdrawal were performed using a large B6D2 F2 cross, short-term selected lines derived from the B6 and D2 progenitor strains, and standard inbred strains. RESULTS: BXD RI strain analysis detected provisional associations between Stxbp1 molecular variants and ethanol consumption, as well as severity of acute ethanol withdrawal, ethanol-conditioned taste aversion, and ethanol-induced hypothermia. Confirmation analyses using three independent genetic models supported the involvement of Stxbp1 in ethanol preference drinking but not in ethanol withdrawal. CONCLUSIONS: Stxbp1 encodes a Sec1/Munc18-type protein essential for vesicular neurotransmitter release. The present study provides supporting evidence for the involvement of Stxbp1 in ethanol preference drinking. 相似文献